Archives
3-Bromopyruvate and Cetuximab Overcome CRC Resistance via Fe
2026-06-09
This study demonstrates that combining 3-Bromopyruvate with cetuximab overcomes drug resistance in colorectal cancer cells by synergistically inducing autophagy-dependent ferroptosis and apoptosis. The work provides mechanistic insight into FOXO3a pathway restoration, with implications for therapeutic strategies targeting refractory metastatic colorectal cancer.
Optimizing Neurotoxicity Assays with Amyloid β-Peptide (1-42
2026-06-08
This article addresses common laboratory challenges in Alzheimer's disease research by examining reproducibility and interpretability in Aβ42 peptide neurotoxicity assays. Drawing on SKU B6057 from APExBIO, it delivers scenario-driven guidance for cell viability workflows, ion channel studies, and microglial activation models. Researchers can leverage these insights to ensure reliable and data-backed experimental outcomes.
Hippo Signaling Modules Shape Hepatobiliary Cell Fate and Ma
2026-06-05
This study uncovers how two distinct Hippo signaling modules, HPO1 and HPO2, regulate the differentiation and maturation of hepatocytes and cholangiocytes during mouse liver development. By integrating spatial transcriptomics and advanced imaging, the research offers new mechanistic insights with implications for liver regeneration and disease.
BV6 IAP Antagonist: Optimizing Apoptosis and Radiosensitizat
2026-06-03
BV6 stands out as a selective IAP antagonist that empowers researchers to drive apoptosis induction, radiosensitization, and disease modeling with reproducible precision. This guide details actionable protocols, advanced use-cases, and troubleshooting tips to maximize the scientific value of BV6 in cancer and endometriosis studies.
Wortmannin: Precision PI3K Inhibitor for Cancer and Viral Re
2026-06-02
Wortmannin enables researchers to dissect the PI3K/Akt/mTOR pathway with unparalleled specificity, facilitating robust workflows in cancer, apoptosis, and emerging antiviral models. Leveraging its nanomolar potency, this selective and irreversible PI3K inhibitor—supplied by APExBIO—supports advanced assay design and troubleshooting for both established and translational experimental paradigms.
Co-Targeting BRD4 and RAC1 Disrupts Oncogenic Axes in Breast
2026-06-02
This study demonstrates that combined inhibition of BET bromodomain BRD4 and RAC1 signaling suppresses growth, stemness, and tumorigenesis across molecular subtypes of breast cancer. Mechanistically, the approach disrupts the c-MYC-G9a-FTH1 axis and downregulates HDAC1, highlighting novel epigenetic vulnerabilities with translational potential.
Q-VD-OPh: Decoding Caspase Inhibition in Apoptosis Assays
2026-06-01
Explore how Q-VD-OPh, a potent pan-caspase inhibitor, enables precise dissection of apoptosis signaling and pore formation dynamics in advanced research models. This article uniquely connects super-resolution mitochondrial studies to practical assay design.
Calpain Inhibitor I, ALLN: Technical Guidance for Research U
2026-05-30
Calpain Inhibitor I (ALLN) is a potent, selective inhibitor for calpain and cathepsin proteases, enabling precise modulation of proteolytic activity in apoptosis assays and ischemia-reperfusion injury models. It is not suitable for diagnostic or medical applications and requires strict handling to maintain activity and minimize off-target effects.
0.4% Trypan Blue Solution: Technical Guide for Cell Viabilit
2026-05-29
0.4% Trypan Blue Solution is an azo dye for cell staining that enables rapid discrimination of viable and non-viable cells in cultured samples. It is essential for accurate cell viability measurement and cell counting, but should not be used for diagnostic or clinical applications. Researchers should follow standardized workflows to ensure consistent results in cytotoxicity assays and related research.
Z-VAD-FMK in Apoptosis Inhibition: Protocols and Bench Insig
2026-05-28
Z-VAD-FMK is the gold-standard pan-caspase inhibitor for dissecting apoptotic and lytic cell death pathways in vitro and in vivo. This guide delivers actionable protocols, troubleshooting strategies, and expert interpretations of recent breakthroughs to ensure your apoptosis research is both mechanistically robust and reproducible.
BMP4-GPX4 Axis Improves RGC Survival in NMDA-Induced Glaucom
2026-05-27
This study demonstrates that activation of the BMP4-GPX4 pathway alleviates ferroptosis and enhances differentiation of retinal stem cells after transplantation in high intraocular pressure glaucoma models. The findings suggest a mechanistically distinct neuroprotective strategy for retinal ganglion cell preservation, with implications for both excitotoxicity research and translational neurodegeneration models.
Sildenafil Citrate: Proteoform-Specific Targeting in Vascula
2026-05-26
Explore the advanced role of Sildenafil Citrate as a cGMP-specific phosphodiesterase type 5 inhibitor in dissecting proteoform-driven vascular signaling. This article uniquely reveals how native membrane proteomics and nuanced drug interactions inform the next generation of precision assays and experimental design.
Redefining Caspase Inhibition: Q-VD(OMe)-OPh in Translationa
2026-05-25
This thought-leadership article explores the mechanistic depth and strategic value of Q-VD(OMe)-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) as a next-generation, broad-spectrum pan-caspase inhibitor for translational researchers. Anchored in contemporary evidence—including recent colorectal cancer resistance studies and comparative performance analyses—this piece guides readers beyond routine apoptosis assays, illuminating how Q-VD(OMe)-OPh enables reproducible, high-fidelity data generation in complex models of cancer biology, neuroprotection, and drug development.
Copper-Based Nanoassemblies Induce Cuproptosis in Cancer The
2026-05-23
This study presents a baicalein–copper nanoassembly that integrates chemodynamic and photodynamic mechanisms to induce cuproptosis for highly effective, multimodal cancer therapy. The nanoplatform demonstrates bone-targeting delivery, robust ROS generation, and significant tumor inhibition, addressing therapy resistance and deep-tissue limitations.
METTL14-m6A Axis in Ulcerative Colitis: Mechanisms and Impli
2026-05-22
The referenced study uncovers how METTL14-mediated m6A modification of lncRNA DHRS4-AS1 modulates inflammation in ulcerative colitis via the miR-206/A3AR axis. These findings clarify a key epigenetic regulatory pathway and highlight therapeutic and research directions for inflammatory bowel disease.
454 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page